Date: 2011-11-15
Type of information: R&D agreement
Compound: new hit compounds against key targets of interest to Almirall
Company: Almirall (Spain) Biofocus, a Galapagos Company (UK - Belgium)
Therapeutic area: Respiratory diseases - Inflammatory diseases
Type agreement: R&D
Action mechanism:
Disease: respiratory and inflammatory conditions
Details: Almirall.and BioFocus have entered into a collaboration agreement to find new hit compounds against key targets of interest to Almirall. These compounds will be used to support projects aimed at the treatment of respiratory andinflammatory conditions. Under the terms of the collaboration, BioFocus will apply its screening technologies and compound collections to an undisclosed number of Almirall projects.
Financial terms:
Latest news: